In unusual language, the Department of Health and Human Services watchdog rebuked Mallinckrodt (MNK) over a proposed plan to provide free amounts of its high-priced Acthar Gel treatment to hospitals and patients, which the agency maintained could create “fraud and abuse risks.”

At issue is an effort by Mallinckrodt to widen the market for its drug, which is used to combat infantile spasms and is a treatment of last resort for other serious maladies. But the decades-old medication has a controversial pricing history that the HHS Office of Inspector General made a strong point of noting in explaining why the company proposal was problematic.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy